Firms

Delos Capital

Delos Capital

deloscapital.com

Delos Capital is a life sciences investment firm founded in 2014 by Henry Chen, with investment and operating staff in Hong Kong, Cambridge and Taipei. It backs biotechnology and medical technology companies developing therapeutics, drug-discovery platforms and devices, with expertise spanning immunology, oncology, cardiovascular disease, neurology and rare diseases. Its portfolio includes computational-biology company TRexBio, gene-delivery developer STRM.BIO, RNA-targeting drug developer Rgenta, stroke-treatment company Imperative Care and neuromodulation developer Tulavi. Delos led TRexBio's USD84 million Series B announced in November 2024 and participated in its USD50 million Series B extension in January 2026. Its current public directory lists six investment professionals and five operations staff. The official portfolio groups investments under Funds I, II and III; fund sizes and closing dates require separate verified fundraising disclosures.

Founded
2014
Type
Venture capital

Funds0

No funds on record yet.

Team

Operations and support

Agnes KwokAgnes KwokFinancial Controller
Andrea LokAndrea LokExecutive Assistant
Carrie GreenawayCarrie GreenawayOffice Manager
Eric HuangEric HuangPartner
Henry ChenHenry ChenFounder & Managing Partner
Lee CooperLee CooperManaging Director
Paul ShenPaul ShenOperations Manager
Tej PavoorTej PavoorPartner
Tim XiaoTim XiaoPartner
Wynne ChanWynne ChanOffice Manager
Yang ChengYang ChengAssociate

Co-investing

General Catalyst
Lightspeed
Longitude Capital
Frazier Life Sciences
Nextech Invest

Investments

$50M2026-01-27TRexBioEli Lilly and Company, SV Health Investors, Johnson & Johnson Innovation – JJDC, Pfizer Ventures, Alexandria Venture Investments, Polaris Partners, Delos Capital, Avego BioScience Capital, Janus Henderson Investors
$84M2024-11-13TRexBioDelos Capital, Eli Lilly and Company, SV Health Investors, Johnson & Johnson Innovation – JJDC, Pfizer Ventures, Alexandria Venture Investments, Polaris Partners, Avego BioScience Capital, Agent Capital
$175M2024-10-23Alpha-9General Catalyst, Lightspeed, Samsara BioCapital, Longitude Capital, Delos Capital, Nextech Invest, Frazier Life Sciences
$175M2024-10-23Alpha-9 Oncology, Inc.General Catalyst, Lightspeed, Samsara BioCapital, Longitude Capital, Delos Capital, Nextech Invest, Frazier Life Sciences
$175M2024-10-23Alpha-9 OncologyLightspeed, General Catalyst, Illumina Ventures, BVF Partners L.P., Longitude Capital, Agent Capital, Delos Capital
$260M2024-07-16Cardurion PharmaceuticalsBain Capital, GV, Farallon Capital Management, Alphabet Inc., Delos Capital
$175M2024Alpha-9 Oncology, Inc.General Catalyst, Lightspeed, Samsara BioCapital, Longitude Capital, Delos Capital, Nextech Invest, Frazier Life Sciences
$260MUnknown dateImperative CareBain Capital, Catalio Capital Management, D1 Capital Partners, Pura Vida Investments, Delos Capital, Ascension Ventures